Developer docs
API playgroundTry for free, no card

Search company profiles

MediCool Technologies

Full company profile

uuid00046nx

Namestring
MediCool Technologies
Legal namestring
MediCool Technologies
Company typeenum
Private
Founded yearint
2015
Descriptiontext

MediCool Technologies is a privately held, pre-revenue medical device company founded in 2015 and headquartered in Traverse City, Michigan. The company is developing a single investigational product, Cool Cardioversion — an implantable device that uses non-destructive thermal cooling of cardiac tissue to terminate atrial fibrillation (A-Fib). This mechanism is positioned as a painless alternative to conventional implantable cardioverter defibrillators (ICDs), which rely on electrical shocks that patients commonly describe as traumatic. Cool Cardioversion is classified by federal law as an investigational device limited to investigational use and has not yet received FDA approval; the company has completed proof-of-concept work and first-in-human feasibility cases.

The underlying technology uses thermal cooling rather than electrical current to restore normal heart rhythm, representing a novel architectural approach to cardioversion. The company is led by a clinical and commercial team anchored by Mayo Clinic electrophysiologists — CTO Dr. Paul Friedman (Chair of Cardiovascular Medicine at Mayo Clinic, 40+ patents, 300+ publications) and CMO Dr. Sam Asirvatham (professor of medicine at Mayo Clinic, 11+ patents in arrhythmia treatment) — alongside CEO Jeff Rynbrandt (19 years medical device commercialization experience) and CFO Peter von Alt (19 years of investment banking with $15B+ in IPOs advised).

MediCool's revenue model is medical-device hardware sales to electrophysiologists, cardiologists, and hospital cardiology departments in the United States, distributed through a direct enterprise field-sales motion post-FDA approval. The company is pre-revenue with no current paying customers; near-term revenue is contingent on regulatory clearance. To date, MediCool has been funded by two National Science Foundation grants (2016: $225K; 2018: $671K) and a 2023 investment from Michigan Rise, the VC subsidiary of the Michigan State University Research Foundation, with primary capital deployment toward R&D, clinical studies, and FDA submission preparation.

Short descriptiontext

MediCool Technologies is a pre-revenue medical device company developing Cool Cardioversion, an investigational implantable device that uses thermal cooling to painlessly terminate atrial fibrillation, targeting electrophysiologists and hospital cardiology departments pending FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTraverse City, United States
HQ citystring
Traverse City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac medical devices, atrial fibrillation treatment, implantable cardioverter devices, thermal cardiac therapy, electrophysiology devices
Industry1 code
PRIMARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Rhythm Management Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

As a medical device company developing an implantable cardioversion device, MediCool will generate revenue through the sale of its Cool Cardioversion device to healthcare providers and hospital systems. The company is pre-revenue as the device is still in development and undergoing clinical studies for FDA approval.

medicooltech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Cool Cardioversion
Description

A painless thermal therapy device that non-destructively cools cardiac tissue to terminate atrial fibrillation without the painful electrical shocks used by traditional ICDs.

medicooltech.com
Core offering1 text field

MediCool Technologies is developing Cool Cardioversion™, an investigational implantable medical device that uses non-destructive thermal cooling of cardiac tissue to painlessly terminate atrial fibrillation and other dangerous cardiac arrhythmias. The device is designed as an alternative to traditional implantable cardioverter defibrillators (ICDs) that deliver painful electrical shocks, intended for use by electrophysiologists, cardiologists, and hospital cardiology departments at the point of care. The product is currently pre-clinical and in early first-in-human clinical studies pending FDA approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • The company has demonstrated feasibility in pre-clinical and first in human cases
Product overview1 text field

MediCool Technologies is a single-product medical device company developing Cool Cardioversion™ — an investigational implantable cardioversion device that uses thermal cooling technology rather than electrical shocks to terminate atrial fibrillation. The device is designed to painlessly restore normal heart rhythm at the point of care, offering an alternative to conventional ICDs. The product is currently in pre-clinical and early human clinical trial stages, pending FDA approval.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MediCool has a partnership with Michigan State University through Michigan Rise's ecosystem. The partnership with Michigan Rise and MSU helps fuel continued innovation in the company's thermal cooling technology for cardiac arrhythmias.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic is the global leader in cardiac rhythm management and the dominant manufacturer of implantable cardioverter defibrillators (ICDs). MediCool's Cool Cardioversion is positioned as an alternative to traditional ICD shock therapy, making Medtronic the most relevant incumbent competitor with overlapping electrophysiology customers and hospital relationships.

2Abbott
TypeBroad incumbent
Description

Abbott is a leading player in cardiac rhythm management with its ICD and CRT-D portfolio, as well as electrophysiology tools. Its installed base, sales infrastructure, and EP lab relationships make it a primary competitor for any next-generation AFib termination device, including Cool Cardioversion.

TypeBroad incumbent
Description

Boston Scientific is a major CRM and electrophysiology player with a deep portfolio of ICDs, ablation catheters, and EP lab solutions. It targets the same electrophysiologists and cardiology departments as MediCool, and would be a likely competitor in any painless or alternative cardioversion modality.

TypeDirect peer
Description

Biotronik is a CRM specialist that manufactures ICDs and pacemakers and competes directly in the implantable cardioverter defibrillator category. As a focused CRM company targeting electrophysiologists, Biotronik is closely comparable to MediCool's positioning in the ICD-alternative space.

TypeEmerging player
Description

AtriCure develops surgical ablation and left atrial appendage management devices for atrial fibrillation, addressing the same patient population as MediCool's Cool Cardioversion. Although it uses a different modality (surgical cryo/radiofrequency ablation), it competes for EP and cardiology procedural spend on AFib treatment.

6Adagio Medical
TypeEmerging player
Description

Adagio Medical is developing cryoablation technologies for atrial fibrillation, including pulsed and ultra-low-temperature cryo catheters. Although a catheter-based approach differs from MediCool's implantable thermal device, both leverage cooling energy to terminate AFib and target the same electrophysiology customer base.

TypeEmerging player
Description

CardioFocus develops laser balloon ablation systems for treating atrial fibrillation. It overlaps with MediCool in treating AFib with an alternative energy modality (laser vs. thermal cooling) and competes for electrophysiology lab procedure volumes.

8Acutus Medical
TypeEmerging player
Description

Acutus Medical develops electrophysiology mapping and ablation technologies for arrhythmia diagnosis and treatment. While focused on mapping and catheter ablation rather than cardioversion, it targets the same electrophysiology specialists and competes for AFib management procedure budgets.

TypeEmerging player
Description

Stereotaxis provides robotic navigation systems for cardiac ablation and other EP procedures. While its technology (robotic magnetic navigation) differs from MediCool's thermal cardioversion approach, it serves the same electrophysiology customers and increasingly competes for advanced AFib treatment workflows.

TypeEmerging player
Description

Artivion (formerly CryoLife) has historic expertise in cryopreservation and cryobiology and is active in cardiac surgery and vascular technologies relevant to cryothermal cardiac therapies. While it focuses on cardiac surgery and tissue preservation rather than implantable cardioversion, its cryothermal capabilities are technically adjacent to MediCool's cooling-based cardioversion approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MediCool Technologies

Cardiac Rhythm Management Devicesmedicooltech.com

MediCool Technologies is a pre-revenue medical device company developing Cool Cardioversion, an investigational implantable device that uses thermal cooling to painlessly terminate atrial fibrillation, targeting electrophysiologists and hospital cardiology departments pending FDA approval.

What MediCool Technologies does

MediCool Technologies is a privately held, pre-revenue medical device company founded in 2015 and headquartered in Traverse City, Michigan. The company is developing a single investigational product, Cool Cardioversion — an implantable device that uses non-destructive thermal cooling of cardiac tissue to terminate atrial fibrillation (A-Fib). This mechanism is positioned as a painless alternative to conventional implantable cardioverter defibrillators (ICDs), which rely on electrical shocks that patients commonly describe as traumatic. Cool Cardioversion is classified by federal law as an investigational device limited to investigational use and has not yet received FDA approval; the company has completed proof-of-concept work and first-in-human feasibility cases.

The underlying technology uses thermal cooling rather than electrical current to restore normal heart rhythm, representing a novel architectural approach to cardioversion. The company is led by a clinical and commercial team anchored by Mayo Clinic electrophysiologists — CTO Dr. Paul Friedman (Chair of Cardiovascular Medicine at Mayo Clinic, 40+ patents, 300+ publications) and CMO Dr. Sam Asirvatham (professor of medicine at Mayo Clinic, 11+ patents in arrhythmia treatment) — alongside CEO Jeff Rynbrandt (19 years medical device commercialization experience) and CFO Peter von Alt (19 years of investment banking with $15B+ in IPOs advised).

MediCool's revenue model is medical-device hardware sales to electrophysiologists, cardiologists, and hospital cardiology departments in the United States, distributed through a direct enterprise field-sales motion post-FDA approval. The company is pre-revenue with no current paying customers; near-term revenue is contingent on regulatory clearance. To date, MediCool has been funded by two National Science Foundation grants (2016: $225K; 2018: $671K) and a 2023 investment from Michigan Rise, the VC subsidiary of the Michigan State University Research Foundation, with primary capital deployment toward R&D, clinical studies, and FDA submission preparation.

MediCool Technologies firmographics

Firmographics
Name
MediCool Technologies
Legal name
MediCool Technologies
Website
https://medicooltech.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
MediCool Technologies is a pre-revenue medical device company developing Cool Cardioversion, an investigational implantable device that uses thermal cooling to painlessly terminate atrial fibrillation, targeting electrophysiologists and hospital cardiology departments pending FDA approval.
Ownership category
akta.pro rank

MediCool Technologies industry classification

Industry
Product category
Cardiac Rhythm Management Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAC
Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac medical devices
  • Atrial fibrillation treatment
  • Implantable cardioverter devices
  • Thermal cardiac therapy
  • Electrophysiology devices

Where MediCool Technologies is headquartered

Location

Headquarters

HQ city
Traverse City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MediCool Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: As a medical device company developing an implantable cardioversion device, MediCool will generate revenue through the sale of its Cool Cardioversion device to healthcare providers and hospital systems. The company is pre-revenue as the device is still in development and undergoing clinical studies for FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MediCool Technologies product offering

Product offering

Core offering

MediCool Technologies is developing Cool Cardioversion™, an investigational implantable medical device that uses non-destructive thermal cooling of cardiac tissue to painlessly terminate atrial fibrillation and other dangerous cardiac arrhythmias. The device is designed as an alternative to traditional implantable cardioverter defibrillators (ICDs) that deliver painful electrical shocks, intended for use by electrophysiologists, cardiologists, and hospital cardiology departments at the point of care. The product is currently pre-clinical and in early first-in-human clinical studies pending FDA approval.

Product overview

MediCool Technologies is a single-product medical device company developing Cool Cardioversion™ — an investigational implantable cardioversion device that uses thermal cooling technology rather than electrical shocks to terminate atrial fibrillation. The device is designed to painlessly restore normal heart rhythm at the point of care, offering an alternative to conventional ICDs. The product is currently in pre-clinical and early human clinical trial stages, pending FDA approval.

Differentiator

Problem solved

Functional benefit

Brands

  • Cool Cardioversion: A painless thermal therapy device that non-destructively cools cardiac tissue to terminate atrial fibrillation without the painful electrical shocks used by traditional ICDs.

Quantifiable outcome

  • The company has demonstrated feasibility in pre-clinical and first in human cases

Companies that use MediCool Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

MediCool Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MediCool Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Michigan State UniversityminorStrategic or Co-development PartnerMediCool has a partnership with Michigan State University through Michigan Rise's ecosystem. The partnership with Michigan Rise and MSU helps fuel continued innovation in the company's thermal cooling technology for cardiac arrhythmias.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

MediCool Technologies competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic is the global leader in cardiac rhythm management and the dominant manufacturer of implantable cardioverter defibrillators (ICDs). MediCool's Cool Cardioversion is positioned as an alternative to traditional ICD shock therapy, making Medtronic the most relevant incumbent competitor with overlapping electrophysiology customers and hospital relationships.
  • Abbott: Abbott is a leading player in cardiac rhythm management with its ICD and CRT-D portfolio, as well as electrophysiology tools. Its installed base, sales infrastructure, and EP lab relationships make it a primary competitor for any next-generation AFib termination device, including Cool Cardioversion.
  • Boston Scientific: Boston Scientific is a major CRM and electrophysiology player with a deep portfolio of ICDs, ablation catheters, and EP lab solutions. It targets the same electrophysiologists and cardiology departments as MediCool, and would be a likely competitor in any painless or alternative cardioversion modality.

Direct peers

  • Biotronik: Biotronik is a CRM specialist that manufactures ICDs and pacemakers and competes directly in the implantable cardioverter defibrillator category. As a focused CRM company targeting electrophysiologists, Biotronik is closely comparable to MediCool's positioning in the ICD-alternative space.

Emerging players

  • AtriCure: AtriCure develops surgical ablation and left atrial appendage management devices for atrial fibrillation, addressing the same patient population as MediCool's Cool Cardioversion. Although it uses a different modality (surgical cryo/radiofrequency ablation), it competes for EP and cardiology procedural spend on AFib treatment.
  • Adagio Medical: Adagio Medical is developing cryoablation technologies for atrial fibrillation, including pulsed and ultra-low-temperature cryo catheters. Although a catheter-based approach differs from MediCool's implantable thermal device, both leverage cooling energy to terminate AFib and target the same electrophysiology customer base.
  • CardioFocus: CardioFocus develops laser balloon ablation systems for treating atrial fibrillation. It overlaps with MediCool in treating AFib with an alternative energy modality (laser vs. thermal cooling) and competes for electrophysiology lab procedure volumes.
  • Acutus Medical: Acutus Medical develops electrophysiology mapping and ablation technologies for arrhythmia diagnosis and treatment. While focused on mapping and catheter ablation rather than cardioversion, it targets the same electrophysiology specialists and competes for AFib management procedure budgets.
  • Stereotaxis: Stereotaxis provides robotic navigation systems for cardiac ablation and other EP procedures. While its technology (robotic magnetic navigation) differs from MediCool's thermal cardioversion approach, it serves the same electrophysiology customers and increasingly competes for advanced AFib treatment workflows.
  • CryoLife (now Artivion): Artivion (formerly CryoLife) has historic expertise in cryopreservation and cryobiology and is active in cardiac surgery and vascular technologies relevant to cryothermal cardiac therapies. While it focuses on cardiac surgery and tissue preservation rather than implantable cardioversion, its cryothermal capabilities are technically adjacent to MediCool's cooling-based cardioversion approach.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

MediCool Technologies social profiles

Digital presence

MediCool Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MediCool Technologies leadership team

Management profile

Number of profiles

Profiles10 records

MediCool Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MediCool Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediCool Technologies

What does MediCool Technologies do?

MediCool Technologies is developing Cool Cardioversion™, an investigational implantable medical device that uses non-destructive thermal cooling of cardiac tissue to painlessly terminate atrial fibrillation and other dangerous cardiac arrhythmias. The device is designed as an alternative to traditional implantable cardioverter defibrillators (ICDs) that deliver painful electrical shocks, intended for use by electrophysiologists, cardiologists, and hospital cardiology departments at the point of care. The product is currently pre-clinical and in early first-in-human clinical studies pending FDA approval.

Is MediCool Technologies a public or private company?

MediCool Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was MediCool Technologies founded?

MediCool Technologies was founded in 2015. It employs 1 to 10 people.

Where is MediCool Technologies based?

MediCool Technologies is headquartered in Traverse City, United States, in the North America region.

How does MediCool Technologies make money?

One revenue line is on record: medical Device Sales.

Who are MediCool Technologies's main competitors?

Broad incumbents on record are Medtronic, Abbott and Boston Scientific. Biotronik is listed as a direct peer. Emerging players are AtriCure, Adagio Medical, CardioFocus, Acutus Medical, Stereotaxis and CryoLife (now Artivion).

Does MediCool Technologies have an API?

No public API is recorded for MediCool Technologies.

What industry is MediCool Technologies in?

MediCool Technologies's product category is Cardiac Rhythm Management Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals